Dec 17 () - Insmed said on Wednesday it had discontinued the development of its ​experimental anti-inflammatory drug to treat a ‌chronic sinus condition after it failed to show benefit in ‌a mid-stage ...

Insmed subsequently decided to discontinue the program with immediate effect. ・The company also announced that it has ...

Insmed Inc. shares sunk in late trading Wednesday after the company said its drug to treat a sinus condition failed in a ...

The latest announcement is out from Insmed ( (INSM) ).

Investing.com -- Insmed Inc (NASDAQ:INSM) stock tumbled 17.2% in after-hours trading Wednesday after the biopharmaceutical company announced its Phase 2b BiRCh study of brensocatib in patients with ...

Depemokimab has been approved by the MHRA as the first and only biologic with twice-yearly dosing to treat asthma and severe ...

GSK plc announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications: ...

Sinus infections, also known as sinusitis, can leave us feeling miserable with symptoms like nasal congestion, facial pain ...

The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

(Alliance News) - GSK PLC on Monday said Exdensur has been approved in the UK, for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps.

The 2025 AAO‐HNSF adult sinusitis guideline, an update of the 2015 guideline, offers evidence-based recommendations on rhinosinusitis management.

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...